For the year ending 2025-12-31, LXRX had -$3,330K decrease in cash & cash equivalents over the period. -$67,851K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -50,341 |
| Depreciation and amortization | 621 |
| Stock-based compensation | 12,517 |
| Amortization of debt-related costs | 1,700 |
| Accretion of marketable securities purchased at a discount | 3,712 |
| Other non-cash adjustments | 1,742 |
| Decrease (increase) in accounts receivable | -1,089 |
| (increase) decrease in inventories | 50 |
| Decrease (increase) in prepaid expenses and other current assets | -1,532 |
| Decrease in other long-term assets | -757 |
| (decrease) increase in accounts payable and other liabilities | -30,222 |
| Net cash used in operating activities | -67,851 |
| Purchases of property and equipment | 0 |
| Purchases of investments | 139,838 |
| Maturities of investments | 252,858 |
| Net cash provided by (used in) investing activities | 113,020 |
| Proceeds from issuance of common stock, net of fees | 0 |
| Proceeds from issuance of common stock for equity incentive plans | 73 |
| Proceeds from issuance of preferred stock, net of fees | 0 |
| Payments for tax withholding on share-based compensation vesting | 572 |
| Debt payments | 48,000 |
| Proceeds from debt borrowings, net of fees | 0 |
| Other debt financing fees | 0 |
| Net cash (used in) provided by financing activities | -48,499 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | -3,330 |
| Cash, cash equivalents, and restricted cash at beginning of year | 66,656 |
| Cash, cash equivalents, and restricted cash at end of year | 63,326 |
LEXICON PHARMACEUTICALS, INC. (LXRX)
LEXICON PHARMACEUTICALS, INC. (LXRX)